Objective To assess the efficacy and safety of the type I interferon receptor antibody, anifrolumab, in patients with active, biopsy-proven, Class III/IV lupus nephritis. Methods This phase II ...
41 St. Joseph's Health Care London and University of Western Ontario, London, Ontario, Canada Objective The 1980 American College of Rheumatology (ACR) classification criteria for systemic sclerosis ...
Correspondence to Dr Dimitrios T Boumpas, Rheumatology and Clinical Immunology Unit, 4th Department of Internal Medicine, "Attikon" University Hospital, Joint Academic Rheumatology Program, National ...
Correspondence to Professor Annamaria Iagnocco, Scienze Cliniche e Biologiche, Università degli Studi di Torino, Turin 10043, Italy; annamaria.iagnocco1{at}gmail.com Objectives Dactylitis is one of ...
Objective Randomised trials of type I anti-CD20 antibodies rituximab and ocrelizumab failed to show benefit in proliferative lupus nephritis (LN). We compared obinutuzumab, a humanised type II ...
Background and purpose Several epidemiologic studies reported increased mortality in patients with GCA, while others found that the overall survival was essentially identical to that of the general ...
Correspondence to Professor Daozhang Cai and Dr Xiaochun Bai, Department of Orthopedics, Academy of Orthopedics - Guangdong Province, Orthopedic Hospital of Guangdong Province, The Third Affiliated ...
Correspondence to Ping-Hsuan Hsieh, Health Economics and Health Technology Assessment, University of Glasgow Institute of Health and Wellbeing, Glasgow G12 8RZ, UK; p.hsieh.1{at}research.gla.ac.uk ...
Study of the genetics of rheumatoid arthritis (RA) began about four decades ago with the discovery of HLA-DRB1. Since the beginning of this century, a number of non-HLA risk loci have been identified ...
Correspondence to Professor Zhuoli Zhang, Department of Rheumatology and Clinical Immunology, Peking University First Hospital, Beijing, China; zhuoli.zhang{at}126.com We conducted a real-world survey ...
Potential and pitfalls of repurposing the CAR-T cell regimen for the treatment of autoimmune disease
Chimeric antigen receptors (CARs) are synthetic proteins designed to direct an immune response toward a specific target and have been used in immunotherapeutic applications through the adoptive ...
Centre for Rheumatology, Department of Medicine, The Middlesex Hospital and University College London, Arthur Stanley House, 40-50 Tottenham Street, London W1T 4NJ, UK Correspondence to: Professor D A ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback